Welcome to our dedicated page for MSP RECOVERY SEC filings (Ticker: MSPRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MSPRZ SEC filings page centers on regulatory documents filed by MSP Recovery, Inc. that describe its redeemable warrants and related corporate events. MSPRZ represents a class of warrants listed on the Nasdaq Capital Market, and information about these securities appears in MSP Recovery, Inc.’s filings under the Securities Exchange Act of 1934.
In an SEC Form 8-K, the company provides a table of securities registered pursuant to Section 12(b), identifying MSPRZ as redeemable warrants, each lot of 4,375 warrants exercisable for one share of Class A common stock at a specified exercise price per share. The same filing also lists the company’s Class A common stock (MSPR) and another warrant class (MSPRW), and confirms that these securities are registered on the Nasdaq Capital Market.
That Form 8-K further reports material events, including confidential settlement agreements with a property and casualty insurer and a drug manufacturer in a pharmaceutical litigation lawsuit. The filing explains that the mediated settlement with the property and casualty insurer involves historical data for claimants, assistance in reconciling assigned Medicare claims, and mechanisms to resolve relevant Medicare claims through cooperative means or binding mediation, along with a cash payment to settle existing historical claims. It also notes a confidential settlement in pharmaceutical litigation alleging overpayments tied to a prescription drug scheme.
On this page, users can access MSP Recovery, Inc.’s SEC filings associated with MSPRZ and related securities. Filings such as Form 8-K provide official descriptions of the warrants, their listing status, and significant legal or corporate events that may affect the company and its capital structure.
MSP Recovery, Inc. disclosed two small, one-time funding arrangements that highlight its constrained liquidity. Through a Hazel Partners Holdings LLC working capital facility, Hazel agreed in its sole discretion to fund a $0.1 million advance for operating expenses under the Operational Collection Floor, funded on March 23, 2026. This advance does not reinstate or reopen any broader availability under the facility, and the company states it has no rights to and no reasonable basis to expect further advances from Hazel.
Separately, MSP Recovery entered into a letter agreement with VRM MSP Recovery Partners, LLC, under which VRM made a one-time advance of recovery proceeds of $0.1 million to support accounts payable. The company must reimburse VRM for this advance and certain prior permitted uses of VRM’s recovery proceeds promptly upon closing of any future loan or other financing, including any debtor-in-possession financing if it operates under Chapter 11 protection. Both fundings are explicitly characterized as one-time accommodations and do not provide ongoing or recurring liquidity.
MSP Recovery, Inc. disclosed two small, one-time funding arrangements and key leadership departures. The company obtained a $0.2 million discretionary advance from Hazel Partners Holdings LLC under its working capital credit facility and a separate $0.2 million one-time advance of recovery proceeds from VRM MSP Recovery Partners, LLC, both primarily for operating needs and accounts payable.
The company emphasizes that its Hazel facility remains fully discretionary, provides no committed liquidity, and that it has no rights to and no reasonable basis to expect further advances. It also states that the VRM advance does not imply any obligation for future funding. In addition, director Ophir Sternberg resigned from the board, and Francisco Rivas‑Vasquez resigned as Chief Financial Officer, with both departures described as not due to disagreements over operations, policies, or practices.
MSP Recovery, Inc. entered into a letter agreement with Hazel Partners Holdings LLC, its working capital lender, under which Hazel made a one-time discretionary advance of $250,000 on January 26, 2026, to be used primarily for operating expenses. This advance increases the amount previously drawn under the facility’s Operational Collection Floor but is described as a standalone accommodation. The company states that this funding does not reinstate or reopen availability under the working capital credit facility and that, apart from this advance, no additional funding is currently available. MSP Recovery further notes it has no rights to, and no reasonable basis to expect, any further advances, and cautions that this payment should not be seen as a sign of future support or ongoing liquidity.
MSP Recovery, Inc. entered into a letter agreement with Hazel Partners Holdings LLC on January 19, 2026 for a one-time advance of $300,000 under its existing working capital credit facility. The funds were provided through the facility’s discretionary Operational Collection Floor and may be used solely for operating expenses.
The advance, funded on January 20, 2026, was subject to conditions under the credit agreement, including no default at the time of funding. MSP Recovery explains that this is a standalone accommodation that does not reinstate or expand availability under the working capital facility, which previously had reached approximately $6.0 million of aggregate advances. The company states that no additional funding is currently available under the facility and that it has no rights to, and no reasonable basis to expect, further advances from Hazel, cautioning that this payment should not be viewed as an indication of ongoing liquidity support.
MSP Recovery reports that it has entered into confidential settlement agreements in ongoing legal matters totaling $2.9 million in cash. Some of this cash will be shared with counterparties under the company’s existing participation and distribution agreements, so not all proceeds will stay with the company.
One preliminary mediated settlement with a property and casualty insurer includes a commitment to provide historical claims data, help reconcile current and future assigned Medicare claims, and make a cash payment to resolve historical claims. A separate confidential settlement was reached with a pharmaceutical defendant in litigation over alleged overpayments. Management notes that these settlements are still being finalized and warns that definitive agreements may not be executed or deliver the expected working capital or operational benefits.